Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Small cell lung carcinoma | D055752 | — | — | 3 | 2 | 3 | — | 1 | 8 |
Lung neoplasms | D008175 | — | C34.90 | 3 | 2 | 3 | — | — | 7 |
Disease progression | D018450 | — | — | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Neoplasms | D009369 | — | C80 | 2 | 2 | — | — | — | 3 |
Prostatic neoplasms | D011471 | — | C61 | 1 | 1 | — | — | — | 1 |
Carcinoma | D002277 | — | C80.0 | 1 | 1 | — | — | — | 1 |
Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | 1 | — | — | — | 1 |
Glioblastoma | D005909 | EFO_0000515 | — | 1 | 1 | — | — | — | 1 |
Melanoma | D008545 | — | — | 1 | 1 | — | — | — | 1 |
Neuroendocrine carcinoma | D018278 | — | — | 1 | 1 | — | — | — | 1 |
Papillary thyroid cancer | D000077273 | — | — | 1 | 1 | — | — | — | 1 |
Drug common name | Rovalpituzumab tesirine |
INN | rovalpituzumab tesirine |
Description | Rovalpituzumab tesirine (Rova-T) is an experimental antibody-drug conjugate targeting the protein DLL3 on tumor cells. It was originally developed by Stemcentrx and was purchased by AbbVie. It was tested for use in small-cell lung cancer, but development was terminated after unsuccessful phase III trial.
|
Classification | Antibody |
Drug class | monoclonal antibodies |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL3990011 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | — |
UNII ID | P256HB60FF (ChemIDplus, GSRS) |